[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

February 2016 | 39 pages | ID: C565EB82EA6EN
La Merie Publishing

US$ 330.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis:

Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

The Competitive Intelligence Report Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines“ provides a competitor evaluation in the field of vaccines on the market or in research & development for prevention of flavivirus-induced diseases as of February 2016. Among the flaviruses covered by the report are Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Zika is an RNA virus transmitted to humans by Aedes mosquitoes. Until recently, it was thought to be relatively harmless with only 20% of infections resulting in mild, short-lived symptoms such as rash, headache and conjunctivitis. Recent reports linking the current South American Zika outbreak to an increase in the number of microencephalic babies born in Brazil and Guillain-Barr? syndrome cases in El Salvador has prompted a reassessment. The severity of these conditions increase drug industry interest in vaccine development. Efforts could focus on modification of vaccines for related diseases.

The Zika virus is closely related to Dengue. Zika virus is a member of the Flaviviridae family, which includes dengue fever, yellow fever, Japanese encephalitis, tick-borne encephalitis, and West Nile viruses. Presently there is no vaccine or specific treatment for Zika.

Companies with experience and expertise with Flavivirus vaccine development are thought to have an advantage over competitors as they might be able to shorten the time until a Zika vaccine can be brought to market.

The report includes a compilation of currently active projects vaccines targeting the flaviruses Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents

1) Zika Virus Vaccines

2) Dengue Virus Vaccines:
  • Live Attenuated or Inactivated Whole-Virus Dengue Virus Vaccines
  • Recombinant Subunit Dengue Virus Vaccines
  • DNA-based Dengue Virus Vaccines
  • Others
3) Chikungunya Virus Vaccines

4) West Nile Virus (WNV) Vaccines

5) Yellow Fever Virus (YFV) Vaccines

6) Japanese Encephalitis Virus Vaccines

7) Tick-Borne Encephalitis (TBE) Virus Vaccines


More Publications